{"groups":[{"description":"This substudy was withdrawn; therefore, no participants were enrolled.","id":"FG000","title":"Substudy A (Relapsed/Refractory Waldenstrom Macroglobulinemia): Brexucabtagene Autoleucel"},{"description":"Participants with Relapsed/Refractory Richter Transformation received the following treatment during the study:\n\nLymphodepletion chemotherapy regimen of fludarabine 30 mg/m\\^2/day intravenously (IV) and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3).\n\nA single IV infusion of brexucabtagene autoleucel at target dose of 2 × 10\\^6 anti-cluster of differentiation 19 (CD19) chimeric antigen receptor (CAR) T cells/kg on Day 0.","id":"FG001","title":"Substudy B (Relapsed/Refractory Richter Transformation): Brexucabtagene Autoleucel"},{"description":"Participants with Relapsed/Refractory Burkitt Lymphoma received the following treatment during the study:\n\nLymphodepletion chemotherapy regimen of fludarabine 30 mg/m\\^2/day intravenously (IV) and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3).\n\nA single IV infusion of brexucabtagene autoleucel at target dose of 2 × 10\\^6 anti-CD19 CAR T cells/kg on Day 0.","id":"FG002","title":"Substudy C (Relapsed/Refractory Burkitt Lymphoma): Brexucabtagene Autoleucel"},{"description":"Participant with Relapsed/Refractory Hairy Cell Leukemia received the following treatment during the study:\n\nLymphodepletion chemotherapy regimen of fludarabine 30 mg/m\\^2/day intravenously (IV) and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3).\n\nA single IV infusion of brexucabtagene autoleucel at target dose of 2 × 10\\^6 anti-CD19 CAR T cells/kg on Day 0.","id":"FG003","title":"Substudy D (Relapsed/Refractory Hairy Cell Leukemia): Brexucabtagene Autoleucel"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"5"},{"groupId":"FG003","numSubjects":"0"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"1"}],"type":"Rolled Over or Consented to a LTFU Study"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"0"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}],"type":"Investigator Decision Due to Progressive Disease"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"Pheresis Lot Failure, Not Proceeding to Chemotherapy or car-t Infusion"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"12"},{"groupId":"FG003","numSubjects":"1"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"12"},{"groupId":"FG003","numSubjects":"1"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"29 participants were screened (Substudy A:1; Substudy B: 10; Substudy C: 16; Substudy D: 2). Substudy A was withdrawn, prior to enrollment of any participants. Therefore, the results below are reported only for Substudies B, C, and D.","recruitmentDetails":"Participants were enrolled at study sites in Netherlands, Italy, Germany, Switzerland, Spain, and the United States."}